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The pathophysiological events leading to hyperacute rejection (HAR) consist of a 
non-specific effector cascade which invokes most. if not all. of the classical mediator 
systems of the acute inflammatory process. This response is generally thought to be 
humorally mediated and has been reported to occur in ABO-incompatible patients 
[I. 2]. in those previously sensitized by a transplant [3]. as a result of multiple blood 
transfusions [4]. secondary to pregnancy (5) or in xenotransplantation [6]. The patho-
genesis of HAR for the kidney and the heart has been extensively investigated and 
fairly well established. The causal event is a specific antibody-mediated injury (IgG 
and IgM) to the vascular endothelium [7]. which is propagated by secondary vaso-
constnction [8]. the recruitment of polymorphonuclear leukocytes (9]. and aggregat· 
ed platelets [10. IIJ. then followed by intra\ascu]ar coagulation [10-12]. The combi-
nation or vasoconstriction and the platelet-leukocyte-plugs leads to occlusion of the 
small arterioles and capillaries with resultant ischemic necrosis of the organ. 
Humorally mediated HAR due to preformed antidonor antibodies also represents 
the mechanism of rejection in discordant xenografts. Support for this hypothesis has 
included the t~lct that heterospecific antibodies were often demonstrable by preo(1\!ra-
tive in \itro testing of the recipient serum [13] and that the physicochemical removal 
of immunoglobulins or the inactivation of complement in the recipient [Jot) often im-
prO\cd xcnograft survival. The process of xenograft rejection is pathophysiologieally 
ycr~ similar. if not identical. to that obsened in ABO blood group major incompati-
hilil~ llr In the presence of serum cylOtoxil: antigraft antibodies [13.15]. In phylo!,!c· 
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netically closer species (concordant), graft rejection appears more cellular in nature 
[6]. Therefore HAR represents a specific and defined, but incompletely understood, 
entity which can be elicited in different transplant situations and in different organs. 
At present, HAR cannot be managed with any significant consistency and, although 
it represents the greatest threat to kidney transplants, it is increasingly becoming an 
important consideration in cardiac and hepatic transplantation. 
Further characterization of the mechanism(s) involved in, and the management of, 
HAR are clearly indicated. Firstly, patients with wide ranging antibodies who have 
become non-candidates for renal transplantation could again be considered. Second-
ly, and of major importance for the future of organ transplantation, is xenotrans-
plantation which remains an important potential solution to the problem of insuffi-
cient donor supply, especially in pediatric patients. While not yet a clinical reality, 
xenotransplantation is the focus of intensive laboratory research. 
Many of the mechanisms involved in the rejection of xenografts have been eluci-
dated and a number of therapeutic approaches are under evaluation. This chapter 
will present an overview of the field and will describe some of the newer concepts 
in the pathophysiology and potential management direction of hyperacute (xeno-
graft) rejection. 
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Fig. I. Schematic illustration of the pathophysiology of hyperacute rejection. 
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Importance o/tlre inflammatory process iuyperacute rejectioll 
Hyperacute rejection fundamentally represents a devascularization in which small 
blood vessels become plugged with coagulation products and fonned blood elements. 
While controversy remains over which antibodies are to blame, and under what cir-
cumstances immediate graft dysfunction occurs, hyperacute rejection must be re-
garded as the product of a complex immune/inflammatory reaction (Figs. 1 and 2). 
The acute inflammatory mediators responsible for tissue injury are derived either 
from plasma proteins or from various types of cells, including polymorphonuclear 
leukocytes (PMNs), platelets. monocytes, macrophages, lymphocytes and endothelial 
cells. The four classic components of the inflammatory response (the complement, 
coagulation, fibrinolysis and the kallikrein-kinin systems) may generate inflammato-
ry plasma proteins responsible for some of the key pathophysiological processes seen 
in HAR. These four protein systems interact with one another during the activation 
process and, furthennore, interact with and activate the cellular elements. In fact, 
it has been the insight recently gained into the cell-derived mediators which has al-
lowed a fuller explanation and understanding of the interrelationships of the various 
pathophysiological processes which are further outlined below. collo~ing the bind-
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ing of antigraft antibody to antigen on the endothelium. all the events that occur 
thereafter are immunologically non-specific. namely. activation of clotting. fibrin 
deposition. fibrinolysis. capillary leaking and the influx of inflammatory cells with 
their own release of mediators and consequent tissue injury. Thus. the process ofhy-
peracute rejection. like that of organ ischemia and necrosis. may involve most of the 
components ofa typical inflammatory response [16]. Obstruction of the small arteries 
by the platelet-neutrophil plugs results in cellular ischemia, which in tum may lead 
to activation of the complement system by the alternate pathway. The release of the 
vasoactive substances C3a and C5a results in enhanced inflammation with neutrophil 
margination and migration to the damaged tissue. This results in neutrophil activa-
tion. with a burst of oxygen consumption and the production of oxygen-derived free 
radicals. for example. via membrane bound NAD(O)H oxidase and release of lysoso-
mal enzyme [16]. The activation of neutrophils leads to an increase in phospholipase 
A2 activity which hydrolyses arachidonic acid from membrane phospholipids [\6]. 
A cascade is initiated which produces a large number of biologically active lipid prod-
ucts including the prostaglandins. leukotrienes and thromboxanes. Two of the more 
important pathophysiological lipid mediators include leukotriene BI. a potent neu-
trophil chemoattractant and thromboxane A2. a potent vasoconstrictor and platelet 
pro-aggregator. 
Acetyl glycerol ether phosphorylcholine (AGEPC). also known as platelet-activat-
ing factor (PAF). is a mediator of many inflammatory reactions [17, 18] and repre-
sents the most recently described and novel class of lipid autocoids (19). \Ioreover. 
PAF can evoke almost all the well-known cardinal signs of acute inflammation and 
probably plays a central role in the induction of tissue injury (25]. The biological ef-
fects of PAF include: (1) platelet and neutrophil aggregation and activation: (2) in-
crease in vascular permeability: (3) smooth muscle contraction: and (4) the release 
of numerous vasoactive and potent biological mediators. Through these properties. 
PAF influences the micro\'asculature of all organs and therefore must be c~ ... nsidered 
a key participant in the disruption of microvascular flow. There is considerable evi-
dence for the candidacy ofPAF as a central and key biological mediator in the patho-
genesis of humorally mediated hyperacute allograft rejection [20-22]. 
As depicted in Figs. I and :!. the inflammatory reactions involved in HAR arc re-
markably complex. Furthermore. they are resilient and redundant in their organiza-
tion. so that the same set of functions can be executed through many alternath'c 
backup systems. Consequently. even if the potent biological activities of one specific 
inflammatory mediator could be completely blocked by highly specific antagonists. 
the combined release of other inflammatory and biologically active agents could easi· 
Iy replace the functions of the missing agent and would be sufficient to mediate an 
unwanted inflammatory response. 
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Experimental manipulation of hyperacqU rejection 
Experimental concordant xenotransplantation 
Concordant xenotransplantation is performed between two species that are closely 
related immunologically, e.g., two different species of subhuman primates or mouse 
and rat. The mechanism of rejection is primarily cellular in nature and is similar to 
classic acute allograft rejection. Therapeutic experimental studies have, for the most 
part, focused predominantly on the use of immunosuppressive regimens. Experimen-
tal models of various concordant combinations have been reported. Significant pro-
longation of cardiac survival in a hamster-rat combination was achieved with the ad-
dition of cyclosporine (CsA) (23). However, virtually toxic levels of this drug were 
required for an effect, suggesting that its use alone may not be appropriate in a clini-
cal setting. Knechtle evaluated total lymphoid irradiation along with CsA in ham-
ster-rat and rabbit-rat combinations [24]. Highly significant prolongation of graft 
survival (> 100 days) was evident in the first combination; however they were unable 
to prolong survival of rabbit-rat cardiac xenografts. Here again. the choice of donor-
recipient combinations was critical. While both species combinations are considered 
concordant. the hamster-rat combination is phylogenetically more closely related 
than the latter. 
Hardy and colleagues reported that peritransplant immunosuppression with a 
combination of palladium-109. hematoporphyrin and anti-lymphocyte globulin pro-
longed cardiac xenograft (hamster-rat) survival IO-fold [25]. Histological examina-
tion of the rejected hearts from treated animals demonstrated minimal lymphocyte 
infiltration or myocardial fiber destruction with patient coronary arteries. These find-
ings were characteristic of the primarily cellular nature of this response. in contrast 
to control animals which consistently exhibited the classic features of hyperacute re-
jection. 
Histopathological studies in these concordant models demonstrated significant 
acute cellular and chronic rejection. with a suggestion of a humoral component. 
Thus. although the immunological reaction in concordant cardiac xenotransplanta-
tion appears to be primarily an aggressive cellular rejection. it is suggested that the 
humoral and perhaps inflammatory component is significant and that it must be ad-
dressed in the management scheme. 
EXf'erim(,lIIal discordant x(,IlOlransplonroTioll 
Discordant cardiac xenotransplantation demonstrates an entirely different immuno-
logical phenomenon. Species differences are sufficiently great that preformed hete-
rospecific antibodies are present in the recipient. Rejection occurs within minutes and 
is humorally mediated. The severity and course of the rejection process. and the resul-
lant pathology resemble the hyperacute rejection seen clinically in situations of ABO 
mismatch or hypersensitization. Although first described in renal transplantation 
[1-6.26]. HAR can also be seen in liver [27] and cardiac [28] transplantation. Experi-
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mental discordant xenotransplantlation has been utilized to further characterize the 
pathological lesions obsent.ed in HAR as well as the mechanism(s) involved. Conven-
tional immunosuppression has generally proven ineffective. 
In a highly discordant combination of guinea pig-rat cardiac graft survival time 
in untreated controls is 16 min. Treatment with cyclosporine, cyclophosphamide or 
splenectomy combined with a 1.5 plasma column exchange, resulted in significantly 
increased graft survival [29]. However, when each treatment regimen was used alone, 
no beneficial effect was observed. Short-term prolongation of discordant xenograft 
survival has also been reported following recipient pretreatment with cobra venom 
factor (CVF) or antiplatelet agents in combination with plasma modifications [30], 
as well as multiple administrations of CVF alone. Further, Shons reported that pre-
treatment with aspirin (80 mgjkg) extended pig-dog renal xenograft survival from 5 
to 21 min [30]. Immediate graft dysfunction has also been prevented by prophylactic 
total-body heparinization in hypersensitized dogs. The effect of anti-platelet agents 
(aspirin) has also been studied in the guinea pig-rat combination, however, successful 
prolongation could not be achieved [3\]. 
Prolongation of xenografts has been reported by transplanting successive organs 
from the same donor [32, 33]. Presumably protection of the final graft was accomp-
lished by antibodies absorbed by the initial graft. In addition, mitigation of the xeno-
graft reaction has also been described following removal of immunoglobulins by 
plasmapheresis [34]. 
Microscopic evaluation of discordant cardiac xenografts are characterized by ca-
pillary congestion and injury, massive extra vascular hemorrhage. interstitial edema, 
ischemic myocardial contracture and lack of interstitial white blood cell infiltration 
[35]. Thus. one of the motivations for studying discordant xenotransplantation is to 
further elucidate the mechanism(s) and pathophysiology of hyperacute rejection as 
well as to investigate various experimental manipulations that might abrogate this 
process. 
When one considers the multiple inflammatory effectors and events involved in the 
pathogenesis of hyperacute rejection. it is not surprising that a successful therapeutic 
approach has not as yet been identified. There ha\'e, however. been significant ad-
vances iO\'olving the early events of the immunological cascade with less success in 
the late. end-stage C\l:!nts. 
Ad.'anus in fh~ mtlnag~menl of h),pertlcuu rejection in xenotransplanlation 
Newer approaches and progress in the abrogation of hyperacute rejection have re-
sulted from studies on two of the more recently recognized and characterized effector 
arms of the secondary response, namely PAF and the arachidonic acid cascade. 
In vitro studies have demonstrated that PAF is released when endothelial cells are 
incubated with antibody to cell surface angiotensin-converting enzyme [20]. This has 
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important implications for hyperacute rejection, in which the specific initiating event 
is a transplantation antigen..atltibody interaction on the endothelial surface. In a 
model of hyperacute renal allograft rejection in sensitized rabbits, PAF was identified 
in the blood effluent from the transplanted kidney, following immediate antibody 
and complement fixation to the endothelium of glomerular and peritubular capilla-
ries [21]. No PAF could be detected in the rabbits without clinical or histological 
signs of hyperacute rejection (i.e., there was no PAF released in syngeneic controls 
of renal allografts transplanted into unsensitized recipients). 
With the availability of specific receptor antagonists of PAF, further insight into 
the role of PAF in the pathogenesis of HAR is now possible. The potential for a new 
method of controlling the effector cascade of HAR by pharmacological intervention 
can now also be explored. 
In a model of ex vivo rabbit heart perfusion with transplantation alloantibodies, 
PAF was released in the absence of inflammatory cells [27]. The addition of a PAF 
receptor antagonist. SRI 63-072 (Sandoz Company). prevented the reduction of cor-
onary flow by 70% within 2-4 min after its addition to the perfusate. Heart action 
was prolonged after the addition of SRI 63-072. however. eventual hyperacute rejec-
tion was not prevented. Implications that PAF may also contribute to cell-mediated 
cardiac allograft rejection have also been reported by Foegh et al. A slight but signifi-
cant prolongation of rat heterotopic heart allograft was achieved following adminis-
tration of a receptor-specific antagonist of PAF. SRI 63-441. when combined with 
prostanoids [36]. 
In a pig-dog renal xenograft model. we have previously reported an improvement 
in graft survival and function following the administration of a receptor-specific an-
tagonist of PAF. SRI 63-441. when combined with prostanoids [37]. Similarly. in a 
cat-rahhit renal transplant model [38]. we demonstrated that recipient pretreatment 
with 4 mg kg SRI 63-441. gi\en intravenously prior to revascularization. significantly 
prolonged xenograft survival compared to vehicle-only treated controls (133.3 ± 
~I~P \S,lj·U ± 5.26 min. P<0.OO2). 
Histological studies of kidneys from SRI 63--l41 treated rahbits showed only mild 
tubular vacuolization at one hour. compared to overt ATN in the control kidneys. 
At II ~ hours both kidneys were similar. with at most 3% glomerular thrombosis and 
ATN. 
While organ graft surival and function was extended in these studies. hyperacute 
rejection was not prevented. The need for a polypharmaceutical approach for the 
treatment of hyperacute rejection is clearly indicated. 
Further evidence supporting the role of PAF in hyperacute rejection [3. 8] has been 
generated through studies in our laboratory utilizing a well-established model of hy-
peracute rejection in rats [391. Inbred Lewis strain (RTII) recipients were sensitized 
by four successive skin grafts from ACT strain (RTI") donors. Control (vehicle only) 
animals consistently rejected donor cardiac grafts in a hyperacute fashion (216 ± 
40.0 min. II = 74). Treatment of sensitized rats with a single intravenous bolus of SRI 
, 
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63-441 prior to revascularization resulted in a varied response. Administration of 5 
or 10 mg/kg failed to demonstrate significant prolongation of graft survival. At a 
dosage of 20 mg kg, three out of eight animals died with pulsating grafts suggesting 
some level of drug toxicity. Significant prolongation of cardiac allograft survival was 
achieved, however, when animals were treated with 15 mg/kg of SRI 63-441 (2475 
± 560 min, n = 20, P < 0.001). In fact, nine of these hearts functioned for 2-5 days 
following transplantation. The combination of a potent immunosuppressant, FK506 
[40] and SRI 63-441 treatment in this model of hyperacute cardiac rejection resulted 
in remarkable prolongation of graft survival in healthy animals. The survival, for the 
most part, far exceeded the allograft survival in nonsensitized recipients (6.3 ± 0.5 
days) and, in several cases, graft survival either approached or exceeded one month. 
These studies provide further insight into the prominent role of PAF in hyperacute 
rejection, its release from transplanted organs and its subsequent recruitment of in-
flammatory cells resulting in graft failure. 
Experimental studies aimed at blocking HAR in its earliest stage, thereby prevent-
ing the initiation of the immunological event, is an area of current interest which may 
have significant implications. Its principle involves the ability of the Staphylococcus 
A exotoxin to bind selectively the Fc receptor of IgG and IgM [41]. By attaching the 
Staph-A protein to a sepharose column. it is possible to run plasma over the column 
and subsequently absorb the immunoglobulin [42]. Instrumentation (Citem-IO. Du-
Pont. Excorim) has been developed with two Staph-A columns, in parallel: as plasma 
is run over one column. the other saturated column is eluted free of bound antibody. 
By immunoadsorbing enough plasma volume. IgG and IgM levels can be decreased 
ten-fold (unpublished data). [n theory. sufficient immunodepletion of preformed 
antibodies might eliminate the endothelial antigen-antibody interaction. and thus ab-
rogate hyperacute rejection by preventing the initiation of the secondary cascade. 
Preliminary work with Sraph-A immunodepletion in a pig-dog xenograft model has 
been performed in our laboratory (43]. demonstrating some prolongation of graft 
survival (unpublished data). Experiments along a similar line. using total plasma ex-
change in a guinea pig-rat cardiac xenograft model have demonstrated even longer 
graft survival [29]. 
Summary 
Since the original description of hyperacute rejection of the kidney. numerous experi-
mental and clinical studies have attempted to define the precise mechanism(s) of this 
process. While our interpretation of HAR has advanced. one must recognize this 
phenomenon as multifactorial and the product of a complex immune inflammatory 
reaction. 
The non-specific effector inflammatory cascade that ensues once an antigen-anti-
body reaction has initiated hyperacute rejection serves as the target for therapeutic 
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intervention by various modalities. Classically, the platelet-coagulation system has 
been considered to be the mosrimportant and has received the greatest attention. 
These therapeutic modalities have included heparin, aspirin, dextran. citrate. de-
fibrinating agents, cobra venom factor, induction of thrombocytopenia by antibo-
dies. and various prostaglandins [28-30]. AIl these approaches have been either too 
toxic or the results too inconclusive to be accepted for generalized use. 
The difficulty in overcoming the inflammatory process in hyperacute rejection and 
in explaining the discrepancies in therapeutic results rest not only in the complexity 
of the biological reactions, but also in their resiliency and redundancy. That is, there 
are numerous alternative mediator pathways that can back up the same set of func-
tions. Thus. the inhibition of one arm of an inflammatory reaction can easily be re-
placed by the release of other inflammatory autocoids with complete mediation of 
the disease process. 
Conclusions 
Future therapeutic approaches in the treatment of hyperacute rejection rely on a bet-
ter understanding of the basic pathophysiological processes of inflammation. It is 
very likely that a combination of approaches. affecting both the immunological and 
non-immunological components of this reaction will be required to achieve complete 
or significant elimination of hyperacute rejection. Perhaps the combination of Staph-
A immunodepletion. PAF inhibition with eicosanoid-mediated vasodilatation. and 
potent new immunosuppressive regimens with such agents as FK 506 will be effec-
tJ\e. At this point. the potential for success in xenotransplantation appears signifi-
cant. 
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